Treatment outcomes of MDR-TB and HIV co-infection in Europe. Issue 6 (8th June 2017)

• Record Type: Journal Article
• Authors: Magis-Escurra, Cecile; Günther, Gunar; Lange, Christoph; Alexandru, Sofia; Altet, Neus; Avsar, Korkut; Bang, Didi; Barbuta, Raisa; Bothamley, Graham; Ciobanu, Ana; Crudu, Valeriu; Davilovits, Manfred; Dedicoat, Martin; Duarte, Raquel; Gualano, Gina; Kunst, Heike; de Lange, Wiel; Leimane, Vaira; McLaughlin, Anne-Marie; Muylle, Inge; Polcová, Veronika; Popa, Christina; Rumetshofer, Rudolf; Skrahina, Alena; Solodovnikova, Varvara; Spinu, Victor; Tiberi, Simon; Viiklepp, Piret; van Leth, Frank
• Is Part Of: European respiratory journal. Volume 49:Issue 6(2017)
• Publication Date: 2017-06-08
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02363-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

The ongoing HIV epidemic and the increasing number of patients with drug-resistant tuberculosis (TB) are seriously hampering global TB-control activities, including those in the World Health Organization (WHO) Region Europe. Overall, the prevalence of HIV co-infection in TB patients increased from 3.4% in 2008 to 8% in 2014 in the region [1]. The prevalence of multidrug-resistant (MDR)-TB (drug resistance against at least isoniazid and rifampicin) reported for Europe – 15% in newly diagnosed TB patients and 48% in previously treated TB patients – is the highest in the world [1]. HIV-positive patients with MDR-TB demonstrate a very low proportion of relapse-free cure http://ow.ly/r9sk30bqLBP